Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors from the central nervous technique, conolidine modulates alternate molecular targets. A Science Advancements review uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability... https://rickeyb430xkl4.blogdun.com/profile